CLDN18 and gastric cancer: They compared immunohistochemistry to MB data in 10 GC patients and verified that the concordance in the expression of CLDN18.2 between CTCs and tissue biopsy is 100% (negative: 3 vs 3; positive: 7 vs 7) (42).